NYSEAMERICAN:NBY - NovaBay Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.50 -0.03 (-1.19 %)
(As of 05/25/2018 02:26 PM ET)
Previous Close$2.50
Today's Range$2.50 - $2.50
52-Week Range$2.25 - $5.00
Volume141 shs
Average Volume8,307 shs
Market Capitalization$52.51 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.79

About NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals logoNovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

Receive NBY News and Ratings via Email

Sign-up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:NBY
CUSIPN/A
Phone+1-510-8998800

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-59.81%
Return on Equity-389.40%
Return on Assets-84.88%

Miscellaneous

EmployeesN/A
Outstanding Shares17,090,000

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."

When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?

NovaBay Pharmaceuticals's stock reverse split on Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) announced its quarterly earnings results on Tuesday, March, 20th. The biopharmaceutical company reported $0.02 EPS for the quarter, topping the Zacks' consensus estimate of ($0.05) by $0.07. The biopharmaceutical company had revenue of $6.32 million for the quarter, compared to the consensus estimate of $5.86 million. NovaBay Pharmaceuticals had a negative net margin of 59.81% and a negative return on equity of 389.40%. View NovaBay Pharmaceuticals' Earnings History.

What price target have analysts set for NBY?

4 Wall Street analysts have issued 1-year price targets for NovaBay Pharmaceuticals' shares. Their predictions range from $4.00 to $8.00. On average, they expect NovaBay Pharmaceuticals' stock price to reach $5.6667 in the next twelve months. View Analyst Ratings for NovaBay Pharmaceuticals.

Who are some of NovaBay Pharmaceuticals' key competitors?

Who are NovaBay Pharmaceuticals' key executives?

NovaBay Pharmaceuticals' management team includes the folowing people:
  • Mr. Mark M. Sieczkarek, Chairman, CEO & Pres (Age 63)
  • Mr. Justin M. Hall, Sr. VP & Gen. Counsel (Age 40)
  • Mr. John J. McGovern, CFO, Treasurer & Principal Accounting Officer
  • Dr. David W. Stroman Ph.D., Sr. VP of Ophthalmic Product Devel. and Chair of Ophthalmology Advisory Board (Age 73)
  • Mr. Lewis J. Stuart BA, MBA, Chief Commercial Officer (Age 59)

Has NovaBay Pharmaceuticals been receiving favorable news coverage?

Press coverage about NBY stock has been trending somewhat negative this week, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NovaBay Pharmaceuticals earned a news impact score of -0.03 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 47.09 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NovaBay Pharmaceuticals' stock price today?

One share of NBY stock can currently be purchased for approximately $2.50.

How big of a company is NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals has a market capitalization of $52.51 million.

How can I contact NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800.


MarketBeat Community Rating for NovaBay Pharmaceuticals (NBY)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  94 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  187
MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote "Outperform" if you believe NBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for NovaBay Pharmaceuticals in the last 12 months. Their average twelve-month price target is $5.6667, suggesting that the stock has a possible upside of 126.67%. The high price target for NBY is $8.00 and the low price target for NBY is $4.00. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.752.80
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.6667$6.00$6.3333$6.25
Price Target Upside: 126.67% upside62.16% upside42.32% upside40.45% upside

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Consensus Price Target History

Price Target History for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/11/2018HC WainwrightSet Price TargetBuy$5.00View Rating Details
3/26/2018Roth CapitalDowngradeBuy ➝ Hold$5.00 ➝ $4.00View Rating Details
11/15/2017LaidlawLower Price TargetBuy ➝ Buy$10.00 ➝ $8.00View Rating Details
8/11/2017Maxim GroupReiterated RatingHoldView Rating Details
2/6/2017Rodman & RenshawInitiated CoverageBuy$6.00View Rating Details
(Data available from 5/25/2016 forward)

Earnings

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Earnings History and Estimates Chart

Earnings by Quarter for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals (NYSEAMERICAN NBY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/20/2018Q4 2017($0.05)$0.02$5.86 million$6.32 millionViewN/AView Earnings Details
11/14/2017Q3($0.07)($0.16)$4.69 million$4.09 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.12)($0.1140)$4.57 million$4.12 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.14)($0.26)$4.08 million$3.70 millionViewN/AView Earnings Details
3/23/2017Q4 2016($0.12)($0.13)$4.03 million$4.08 millionViewN/AView Earnings Details
11/10/2016Q316($0.16)($0.34)$3.02 million$3.40 millionViewN/AView Earnings Details
8/11/2016Q216($0.30)($0.36)$1.76 million$2.70 millionViewListenView Earnings Details
5/12/2016Q116($0.68)($1.24)$1.84 million$1.70 millionViewListenView Earnings Details
3/3/2016Q415($1.36)($1.26)$1.43 million$1.60 millionViewN/AView Earnings Details
11/19/2015Q315($0.07)($0.07)$1.06 million$1.20 millionViewListenView Earnings Details
8/13/2015Q215($0.07)($0.07)$610.00 million$1.01 millionViewListenView Earnings Details
5/14/2015Q1($0.06)($0.09)$0.54 millionViewN/AView Earnings Details
3/26/2015Q414($0.07)($0.09)$0.49 millionViewN/AView Earnings Details
11/12/2014Q314($0.09)($0.08)$0.15 millionViewN/AView Earnings Details
7/31/2014($0.09)($0.06)$0.12 millionViewN/AView Earnings Details
5/1/2014Q114($0.11)($0.08)$0.19 millionViewN/AView Earnings Details
3/7/2014Q4 2013$2.50$0.37 millionViewN/AView Earnings Details
11/12/2013Q3($0.10)$1.10 millionViewN/AView Earnings Details
8/1/2013Q2 2013($2.75)$0.85 millionViewN/AView Earnings Details
5/2/2013Q113($0.07)($0.11)$1.18 million$0.96 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.09)($0.08)$1.50 millionViewN/AView Earnings Details
8/9/2012Q2 2012($2.00)($1.95)ViewN/AView Earnings Details
5/3/2012Q1 2012($1.75)($2.23)ViewN/AView Earnings Details
3/27/2012Q4 2011($2.30)ViewN/AView Earnings Details
11/7/2011Q3 2011($1.75)($0.30)ViewN/AView Earnings Details
8/10/2011Q2 2011($2.00)$0.45ViewN/AView Earnings Details
5/16/2011Q1 2011($2.00)ViewN/AView Earnings Details
3/10/2011Q4 2010($2.00)$0.18ViewN/AView Earnings Details
11/12/2010Q3 2010($1.75)($1.75)ViewN/AView Earnings Details
8/12/2010Q2 2010($1.75)($1.28)ViewN/AView Earnings Details
5/12/2010Q1 2010($2.00)($1.75)ViewN/AView Earnings Details
3/30/2010Q4 2009($0.50)$3.58ViewN/AView Earnings Details
11/13/2009Q3 2009($0.25)($0.13)ViewN/AView Earnings Details
8/14/2009Q2 2009($2.50)($0.33)ViewN/AView Earnings Details
5/18/2009Q1 2009($1.25)($0.38)ViewN/AView Earnings Details
4/1/2009Q4 2008($2.50)($1.75)ViewN/AView Earnings Details
11/14/2008Q3 2008($3.75)($1.73)ViewN/AView Earnings Details
8/14/2008Q2 2008($3.25)($2.83)ViewN/AView Earnings Details
5/14/2008Q1 2008($3.15)ViewN/AView Earnings Details
3/11/2008Q4 2007($2.13)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

NovaBay Pharmaceuticals (NYSEAMERICAN NBY) Insider Trading and Institutional Ownership History

Insider Trading History for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals (NYSEAMERICAN NBY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/25/2017Jacques BonneauDirectorBuy25,000$0.22$5,500.00
10/18/2017Jacques BonneauDirectorBuy50,000$0.16$8,000.00
9/8/2017Jean-Sébastien DavidDirectorBuy12,300$0.20$2,460.00
9/7/2017Jean-Sébastien DavidDirectorBuy15,000$0.20$3,000.00
9/6/2017Claude DufresneDirectorBuy10,000$0.21$2,100.00
8/21/2017Claude DufresneDirectorBuy10,000$0.13$1,300.00
6/26/2017Serge SavardDirectorBuy52,000$0.18$9,360.00
6/23/2017Serge SavardDirectorBuy10,000$0.17$1,700.00
6/21/2017Serge SavardDirectorBuy18,500$0.17$3,145.00
6/20/2017Serge SavardDirectorBuy101,000$0.17$17,170.00
6/19/2017Serge SavardDirectorBuy18,500$0.17$3,145.00
4/26/2017Claude DufresneDirectorBuy2,000$0.76$1,520.00
3/6/2017Jean-Sébastien DavidDirectorBuy3,820$0.81$3,094.20
1/12/2017Claude DufresneDirectorSell21,000$0.77$16,170.00
8/20/2015Ramin NajafiCEOBuy12,000$0.47$5,640.00View SEC Filing  
3/3/2015Pharma (Singapore) Pte PioneerMajor ShareholderBuy2,590,000$0.60$1,554,000.00View SEC Filing  
3/3/2015Ramin NajafiChairmanBuy166,666$0.60$99,999.60View SEC Filing  
12/12/2014Ramin NajafiChairmanBuy50,000$0.65$32,500.00View SEC Filing  
12/12/2014Thomas J PaulsonCFOBuy10,000$0.68$6,800.00View SEC Filing  
12/11/2014Ramin NajafiChairmanBuy20,000$0.60$12,000.00View SEC Filing  
12/9/2014Thomas J PaulsonCFOBuy10,000$0.67$6,700.00View SEC Filing  
12/5/2014Ramin NajafiChairmanBuy25,000$0.65$16,250.00View SEC Filing  
12/2/2014Ramin NajafiChairmanBuy18,000$0.71$12,780.00View SEC Filing  
12/2/2014Tony D.S. WicksDirectorSell20,000$0.70$14,000.00View SEC Filing  
6/4/2014Mark M SieczkarekDirectorBuy4,800$0.89$4,272.00View SEC Filing  
5/19/2014Mark M SieczkarekDirectorBuy25,000$0.88$22,000.00View SEC Filing  
5/13/2014Pioneer Pharma Holdings ChinaMajor ShareholderBuy65,065$0.99$64,414.35View SEC Filing  
5/12/2014Pioneer Pharma Holdings ChinaMajor ShareholderBuy116,107$0.99$114,945.93View SEC Filing  
5/9/2014Pioneer Pharma Holdings ChinaMajor ShareholderBuy318,828$0.99$315,639.72View SEC Filing  
12/2/2013Pioneer Pharma Holdings ChinaMajor ShareholderBuy5,000,000$1.14$5,700,000.00View SEC Filing  
12/11/2012Xinzhou LiInsiderBuy120,000$1.20$144,000.00View SEC Filing  
12/6/2012Ramin NajafiChairmanBuy20,000$1.24$24,800.00View SEC Filing  
12/6/2012Thomas J PaulsonCFOBuy10,000$1.24$12,400.00View SEC Filing  
10/31/2012Area Pioneer Pharma Co. NaquMajor ShareholderBuy1,200,000$1.25$1,500,000.00View SEC Filing  
9/13/2012Xinzhou LiMajor ShareholderBuy800,000$1.25$1,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

NovaBay Pharmaceuticals (NYSEAMERICAN NBY) News Headlines

Source:
DateHeadline
NovaBay Pharmaceuticals, Inc. (NBY) Receives Consensus Rating of "Hold" from AnalystsNovaBay Pharmaceuticals, Inc. (NBY) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - May 21 at 1:52 AM
NovaBay Pharmaceuticals (NBY) CEO Mark Sieczkarek on Q1 2018 Results - Earnings Call TranscriptNovaBay Pharmaceuticals' (NBY) CEO Mark Sieczkarek on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 10:24 AM
HC Wainwright Reaffirms Buy Rating for NovaBay Pharmaceuticals (NBY)HC Wainwright Reaffirms Buy Rating for NovaBay Pharmaceuticals (NBY)
www.americanbankingnews.com - May 11 at 5:48 PM
NovaBay Pharmaceuticals Reports First Quarter 2018 Financial ResultsNovaBay Pharmaceuticals Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 10 at 4:24 PM
NovaBay Pharmaceuticals to Hold First Quarter 2018 Conference Call on May 10, 2018NovaBay Pharmaceuticals to Hold First Quarter 2018 Conference Call on May 10, 2018
finance.yahoo.com - May 7 at 9:29 AM
NovaBay Pharmaceuticals, Inc. (NBY) Receives Consensus Recommendation of "Hold" from AnalystsNovaBay Pharmaceuticals, Inc. (NBY) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 26 at 1:42 AM
NovaBay Pharmaceuticals (NBY) Rating Increased to Hold at Zacks Investment ResearchNovaBay Pharmaceuticals (NBY) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 10 at 9:45 AM
NovaBay Pharmaceuticals (NBY) Upgraded to Hold by Zacks Investment ResearchNovaBay Pharmaceuticals (NBY) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - March 27 at 7:27 PM
Roth Capital Downgrades NovaBay Pharmaceuticals (NBY) to NeutralRoth Capital Downgrades NovaBay Pharmaceuticals (NBY) to Neutral
www.streetinsider.com - March 26 at 4:10 PM
NovaBay Pharmaceuticals (NBY) Downgraded to "Hold" at Roth CapitalNovaBay Pharmaceuticals (NBY) Downgraded to "Hold" at Roth Capital
www.americanbankingnews.com - March 26 at 10:33 AM
HC Wainwright Analysts Give NovaBay Pharmaceuticals (NBY) a $6.00 Price TargetHC Wainwright Analysts Give NovaBay Pharmaceuticals (NBY) a $6.00 Price Target
www.americanbankingnews.com - March 21 at 3:57 PM
NovaBay Pharmaceuticals Reports 2017 Fourth Quarter and Full Year Financial ResultsNovaBay Pharmaceuticals Reports 2017 Fourth Quarter and Full Year Financial Results
finance.yahoo.com - March 20 at 4:10 PM
BRIEF-Jinzi Hams Unit Scraps Plan To Invest In Novabay Pharma, To Boost Asset Management Subsidiarys CapitalBRIEF-Jinzi Ham's Unit Scraps Plan To Invest In Novabay Pharma, To Boost Asset Management Subsidiary's Capital
finance.yahoo.com - March 12 at 5:19 PM
NovaBay Pharmaceuticals, Inc. (NBY) Given Consensus Rating of "Hold" by BrokeragesNovaBay Pharmaceuticals, Inc. (NBY) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 7 at 1:50 AM
NovaBay Pharmaceuticals to Hold 2017 Fourth Quarter and Full Year Conference Call on March 20, 2018NovaBay Pharmaceuticals to Hold 2017 Fourth Quarter and Full Year Conference Call on March 20, 2018
finance.yahoo.com - February 21 at 9:52 AM
NovaBay Pharmaceuticals (NBY) Raised to Hold at Zacks Investment ResearchNovaBay Pharmaceuticals (NBY) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - February 15 at 6:26 AM
Your Daily Pharma Scoop: Akebia Update, Rexahn Data, Concert Commences EnrollmentYour Daily Pharma Scoop: Akebia Update, Rexahn Data, Concert Commences Enrollment
seekingalpha.com - February 14 at 9:01 AM
NovaBay Pharmaceuticals Completes $6.0 Million Private PlacementNovaBay Pharmaceuticals Completes $6.0 Million Private Placement
finance.yahoo.com - February 12 at 8:57 AM
NovaBay Pharmaceuticals, Inc. (NBY) Given Average Rating of "Hold" by AnalystsNovaBay Pharmaceuticals, Inc. (NBY) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - February 10 at 1:48 AM
NovaBay Pharmaceuticals (NBY) Downgraded to Sell at Zacks Investment ResearchNovaBay Pharmaceuticals (NBY) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - February 9 at 12:06 PM
NovaBay Pharma (NBY) Enters Share Purchase Agreement for Sale of 1,700,000 Shares of Common StockNovaBay Pharma (NBY) Enters Share Purchase Agreement for Sale of 1,700,000 Shares of Common Stock
www.streetinsider.com - February 6 at 4:33 PM
NovaBay Pharmaceuticals, Inc. (NBY) Short Interest Up 32.1% in DecemberNovaBay Pharmaceuticals, Inc. (NBY) Short Interest Up 32.1% in December
www.americanbankingnews.com - January 10 at 6:06 PM
NovaBay Pharmaceuticals Announces Preliminary Sales for 2017 Fourth Quarter and Full YearNovaBay Pharmaceuticals Announces Preliminary Sales for 2017 Fourth Quarter and Full Year
finance.yahoo.com - January 8 at 8:04 AM
NovaBay Pharmaceuticals Gets Stockholder Approval for Proposed $10.32 Mln Financing DealNovaBay Pharmaceuticals Gets Stockholder Approval for Proposed $10.32 Mln Financing Deal
www.nasdaq.com - December 22 at 9:17 AM
NovaBay Pharmaceuticals Receives Stockholder Approval for Proposed $10.32 Million Financing AgreementNovaBay Pharmaceuticals Receives Stockholder Approval for Proposed $10.32 Million Financing Agreement
finance.yahoo.com - December 22 at 9:17 AM
NovaBay Pharmaceuticals, Inc. (NBY) Given Average Rating of "Hold" by BrokeragesNovaBay Pharmaceuticals, Inc. (NBY) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 22 at 2:06 AM
NovaBay Pharmaceuticals Regains Compliance with NYSE American Continued Listing StandardsNovaBay Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards
finance.yahoo.com - December 21 at 9:07 AM
ETFs with exposure to NovaBay Pharmaceuticals, Inc. : December 19, 2017ETFs with exposure to NovaBay Pharmaceuticals, Inc. : December 19, 2017
finance.yahoo.com - December 19 at 5:20 PM
NovaBay Pharma (NBY) Names Lewis Stuart CCONovaBay Pharma (NBY) Names Lewis Stuart CCO
www.streetinsider.com - December 6 at 5:39 PM
ETFs with exposure to NovaBay Pharmaceuticals, Inc. : November 30, 2017ETFs with exposure to NovaBay Pharmaceuticals, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 5:18 PM
NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 9:09 AM
NovaBay Pharmaceuticals, Inc. (NBY) Given Consensus Recommendation of "Hold" by BrokeragesNovaBay Pharmaceuticals, Inc. (NBY) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 27 at 2:06 AM
HC Wainwright Analysts Give NovaBay Pharmaceuticals, Inc. (NBY) a $6.00 Price TargetHC Wainwright Analysts Give NovaBay Pharmaceuticals, Inc. (NBY) a $6.00 Price Target
www.americanbankingnews.com - November 19 at 5:38 PM
Laidlaw Trims NovaBay Pharmaceuticals, Inc. (NBY) Target Price to $8.00Laidlaw Trims NovaBay Pharmaceuticals, Inc. (NBY) Target Price to $8.00
www.americanbankingnews.com - November 19 at 11:14 AM
NovaBay Pharmaceuticals, Inc. (NBY) Posts Quarterly  Earnings Results, Misses Estimates By $0.09 EPSNovaBay Pharmaceuticals, Inc. (NBY) Posts Quarterly Earnings Results, Misses Estimates By $0.09 EPS
www.americanbankingnews.com - November 15 at 1:05 PM
NovaBay Pharmaceuticals, Inc. (NBY) Price Target Cut to $8.00NovaBay Pharmaceuticals, Inc. (NBY) Price Target Cut to $8.00
www.americanbankingnews.com - November 15 at 8:28 AM
NovaBay Pharmaceuticals (NBY) CEO Mark Sieczkarek on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaNovaBay Pharmaceuticals (NBY) CEO Mark Sieczkarek on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 15 at 6:40 AM
BRIEF-Jinzi Hams unit to invest in Novabay Pharma and become its biggest shareholderBRIEF-Jinzi Ham's unit to invest in Novabay Pharma and become its biggest shareholder
finance.yahoo.com - November 15 at 6:40 AM
NovaBay Pharmaceuticals, Inc. to Host Earnings CallNovaBay Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 15 at 6:40 AM
NovaBay Pharmaceuticals Reports Third Quarter 2017 Financial ResultsNovaBay Pharmaceuticals Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 15 at 6:40 AM

SEC Filings

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

NovaBay Pharmaceuticals (NYSEAMERICAN NBY) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.